Artelo Biosciences ARTL

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.01 (-0.99%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Artelo Biosciences (ARTL)
    Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1

    • Market Cap

      $3.28 Million

    • Total Outstanding Shares

      3.28 Million Shares

    • Total Employees

      6

    • Dividend

      No dividend

    • IPO Date

      October 13, 2015

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      505 lomas santa fe, suite 160, Solana beach, CA, 92075

    • Homepage

      https://www.artelobio.com

    Historical Stock Splits

    If you bought 120 shares of ARTL before June 21, 2019, you'd have 1 share today.
    Execution DateSplit Amount
    August 10, 20221-for-15 (Reverse Split)
    June 21, 20191-for-8 (Reverse Split)

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Financing Activities, Continuing$112,000
    Net Cash Flow From Investing Activities$7.77 Million
    Exchange Gains/Losses$-8,000
    Net Cash Flow From Operating Activities, Continuing$-8.35 Million
    Net Cash Flow From Financing Activities$112,000
    Net Cash Flow$-477,000

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Income/Loss From Continuing Operations Before Tax$-9.83 Million
    Net Income/Loss Available To Common Stockholders, Basic$-9.83 Million
    Other Operating Expenses$4.12 Million
    Net Income/Loss$-9.83 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Income/Loss From Continuing Operations After Tax$-9.83 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-9.82 Million
    Comprehensive Income/Loss$-9.82 Million
    Other Comprehensive Income/Loss$1,000

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Non-current Assets$102,000
    Liabilities$1.84 Million
    Equity Attributable To Noncontrolling Interest$0
    Assets$4.70 Million
    Equity$2.86 Million
    Noncurrent Assets$2.14 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ARTL from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.